These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 9746960)
1. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure]. Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960 [TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure. Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275 [TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E1 infusion compared with prostacyclin infusion in patients with refractory heart failure: effects on hemodynamics and neurohumoral variables. Pacher R; Stanek B; Hülsmann M; Bojic A; Berger R; Frey B; Siegel A; Kos T; Ogris E; Grimm M; Laufer G J Heart Lung Transplant; 1997 Aug; 16(8):878-81. PubMed ID: 9286780 [TBL] [Abstract][Full Text] [Related]
4. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery. Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617 [TBL] [Abstract][Full Text] [Related]
5. Effect of prostaglandin E1 infusion on kidney function in patients with severe heart failure. Wutte M; Hülsmann M; Berger R; Siegel A; Stanek B; Pacher R J Heart Lung Transplant; 1996 Mar; 15(3):317-8. PubMed ID: 8777218 [No Abstract] [Full Text] [Related]
6. Acceptance of a pump-driven infusion therapy with prostaglandin E1 as a bridge to heart transplantation. Daneschvar H; Pacher R; Rödler S; Stanek B; Hülsmann M; Grimm M; Laufer G; Wolner E; Bunzel B Wien Klin Wochenschr; 1996; 108(16):510-4. PubMed ID: 8840497 [TBL] [Abstract][Full Text] [Related]
7. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure. Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976 [TBL] [Abstract][Full Text] [Related]
9. [Effect of prostaglandin E1 on extravascular lung water in patients with severe heart failure]. Lenz K; Kranz A; Kramer L; Buder R; Schollmayer E Wien Klin Wochenschr; 1996; 108(16):505-9. PubMed ID: 8967094 [TBL] [Abstract][Full Text] [Related]
10. [Role of prostaglandins in regulation of kidney function in heart failure]. Riegger AJ Herz; 1991 Apr; 16(2):116-23. PubMed ID: 2066053 [TBL] [Abstract][Full Text] [Related]
11. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure. Stanek B; Pacher R Jpn Heart J; 1997 Jan; 38(1):53-65. PubMed ID: 9186281 [TBL] [Abstract][Full Text] [Related]
12. Relationship between kidney function, hemodynamic variables and circulating big endothelin levels in patients with severe refractory heart failure. Kos T; Pacher R; Wimmer A; Bojic A; Hülsmann M; Frey B; Mayer G; Yilmaz N; Skvarilova L; Spinar J; Vitovec J; Toman J; Woloszcuk W; Stanek B Wien Klin Wochenschr; 1998 Feb; 110(3):89-95. PubMed ID: 9553203 [TBL] [Abstract][Full Text] [Related]
13. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Cotter G; Weissgarten J; Metzkor E; Moshkovitz Y; Litinski I; Tavori U; Perry C; Zaidenstein R; Golik A Clin Pharmacol Ther; 1997 Aug; 62(2):187-93. PubMed ID: 9284855 [TBL] [Abstract][Full Text] [Related]
14. [Recombinant human brain natriuretic peptide on the cardiac hemodynamics and renal function in dogs with heart failure]. Xu XW; Zeng GY; Yang Y; Liu HX Yao Xue Xue Bao; 2002 Oct; 37(10):758-62. PubMed ID: 12567856 [TBL] [Abstract][Full Text] [Related]
15. [Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction]. Koch JA; Sketch M; Brinker J; Bernink PJ Rofo; 1999 Jun; 170(6):557-63. PubMed ID: 10420905 [TBL] [Abstract][Full Text] [Related]
16. Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration. Serra W; Musiari L; Ardissino D; Gherli T; Montanari A Int J Cardiol; 2011 Jan; 146(1):e10-5. PubMed ID: 19176262 [TBL] [Abstract][Full Text] [Related]
17. The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. The Prostaglandin E1 Study Group. Slotman GJ; Kerstein MD; Bone RC; Silverman H; Maunder R; Hyers TM; Ursprung JJ J Trauma; 1992 Apr; 32(4):480-8; discussion 488-9. PubMed ID: 1569622 [TBL] [Abstract][Full Text] [Related]
18. [The dobutamine-dopamine combination versus amrinone in congestive heart failure with a marked edematogenic sign complicated by functional kidney failure. A comparison between 2 different models of inotropic stimulation and diuresis potentiation]. De Vecchis R; Pucciarelli G; Nocerino L; Cocozza M; Setaro A; Torre G; Imperatore F Minerva Cardioangiol; 1998 May; 46(5):163-74. PubMed ID: 9842199 [TBL] [Abstract][Full Text] [Related]
19. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657 [TBL] [Abstract][Full Text] [Related]
20. [Neurohumoral and hemodynamic effects in combination therapy of enoximone and dopamine]. Mitrovic V; Neuzner J; Opper H; Thormann J; Schlepper M Z Kardiol; 1994; 83 Suppl 2():37-48. PubMed ID: 8091823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]